- Visibility 61 Views
- Downloads 14 Downloads
- Permissions
- DOI 10.18231/j.aprd.2023.024
-
CrossMark
- Citation
Prosthodontic rehabilitation of patients with Rhinocerebral mucormycosis: An update of evidence
Abstract
Mucormycosis is a devastating disease with serious manifestations in the affected individuals. It spreads through angioinvasion, and the spores have high affinity for olfactory epithelium, and pterygomandibular raphe of immunocompromised patients. Surgical debridement of invaded structures leads to extensive defects, which need prosthodontic rehabilitation to improve the quality of life of the patients. This article is compilation of data presented in literature to showcase the patients who were treated with maxillary obturators to manage post mucormycosis intraoral defects. Lacunae in presentation of clinical cases with future recommendations have also been discussed in brief.
Introduction
Mucormycosis is a fatal disease with serious manifestations as it leads to extensive tissue necrosis and spreads rapidly through vascular route.[1] Incidental findings while examining a patient for common dental pain or facial swelling may benefit in the early diagnosis of the disease. Depending upon the type and stage of disease, a course of treatment may lead to aggressive resection of various structures such as the maxilla, alveolus, and extraction of otherwise healthy teeth. Rhino orbito cerebral mucormycosis (RCOM), which is reported to be the most common type in developing countries, may also lead to additional loss of orbital and associated facial structures. [2] Consequences include a physically debilitated patient with enormous psychological trauma. Prosthodontists play a pivotal role in improving the functional and overall quality of life of such patients by fabricating maxillary obturators and facial prostheses.
Santos et al, in a recent article on Mucormycosis, presented a review of literature based on PubMed search, wherein the authors included data from 19 papers including their own case.[3] The authors highlighted that there were only 3 documented cases with history of Mucormycosis and rehabilitation with palatal obturator between 2007-2019. With no intention to negate the efforts of the authors and based on my experience with rehabilitation of patients with maxillofacial defects, a literature search was performed to update the evidence on patients who suffered with Mucormycosis who underwent prosthodontic rehabilitation with obturators.
|
Author/ Year Country |
Age/ Gender |
Genus/ Species |
Risk Factors |
Location |
Imaging tests |
Treatment |
Rehabilitation |
Follow-up |
Articles between 2007-2019 |
|||||||||
1. |
Pruthi G et al., 2010 [4], India |
55/ Male |
Unspecified |
Diabetes, Rhino cerebral mucormycosis |
Aramany Class IV |
Unspecified |
Right maxillary resection |
Definitive maxillary obturator and silicone eye prosthesis |
Unspecified |
2. |
I. Abu El-Naaj et al./ 2013 [5], Israel, case 1 |
15/ Female |
Zygomycete compatible with mucormycosis |
Acute Lymphoid Leukemia, Rhinocerebral Mucormycosis |
Aramany Class IV |
Computed tomography, MRI, Fiberoptic Endoscopic Sinus Surgery (FESS) for tissue culture and debridement |
Liposomal Amphotericin B Posaconazole Left total hemimaxillectomy, left ethmoidectomy and partial left sphenoidectomy |
Definitive maxillary obturator |
18-month follow-up |
|
I. Abu El-Naaj et al./ 2013 [5], Israel, case 2 |
56/ Female |
Unspecified |
B-cell lymphoma Rhinocerebral Mucormycosis |
Unspecified |
Computed tomography |
Subtotal maxillectomy. Isovuconazole, Amphotericin B, Voriconazole Posaconazole |
Could not be done |
Death |
|
I. Abu El-Naaj et al./ 2013 [5], Israel, case 3 |
25/ Female |
Unspecified |
Acute Myeloid Leukemia Rhinocerebral Mucormycosis |
Unspecified |
Computed tomography |
Total maxillectomy. Amphotericin-B Posaconazole, |
Could not be done |
Death |
|
I. Abu El-Naaj et al./ 2013 [5], Israel, case 4 |
22/ Male |
Unspecified |
Chronic Myeloid Leukemia Rhinocerebral Mucormycosis |
Unspecified |
Computed tomography |
Subtotal maxillectomy. Amphotericin-B, Voriconazole |
Could not be done |
Death |
|
I. Abu El-Naaj et al./ 2013 [5], Israel, case 5 |
75/ Male |
Unspecified |
Acute Myeloid leukemia Rhinocerebral Mucormycosis |
Unspecified |
Computed tomography |
Subtotal maxillectomy. Amphotericin-B, Voriconazole |
Could not be done |
Death |
|
I. Abu El-Naaj et al./ 2013 [5], Israel, case 6 |
64 / Female |
Unspecified |
Aplastic anemia Rhinocerebral Mucormycosis |
Unspecified |
Computed tomography |
Total maxillectomy. Amphotericin-B, Voriconazole |
Could not be done |
Death |
3. |
Hatami et al./ 2013 [6], Iran |
65/ Male |
Unspecified |
Diabetes, Diabetic keto acidosis, Rhinocerebral mucormycosis |
Open communication between the oral, nasal, and orbital cavities*** |
Not specified |
Resected portions included anterior part of hard palate, nasal septum and conchae, left maxillary sinus, and orbital contents |
Magnet retainer intraoral definitve obturator and facial prosthesis |
2 years |
4. |
Gowda et al./ 2013 [7], India |
52/Male |
Unspecified |
Type II Diabetes Mellitus |
Aramany Class 1 |
Panoromic radiograph |
Left hemimaxillectomy |
Interim hollow bulb obturator, Definitve implant and magnet retained obturator |
6 months |
5. |
Vidyasankari et al./ 2014 [8], India |
62/ Male |
Unspecified |
Rhino cerebral mucormycosis |
Maxilla*** |
Not specified |
Left eye exenteration and left maxillectomy |
Orbital prosthesis and a definitive intra-oral obturator |
Not specified |
6. |
Faheemuddin M et al./ 2014 [9], Pakistan |
49/ Female |
Unspecified |
Diabetes, Hypertension, |
Maxillae*** |
Not specified |
Bilateral total maxillectomy |
Definitive Maxillary obturator |
2 months |
7. |
Shah R et al./ 2014 [10], India, Case 1 |
48/ Female |
Unspecified |
Mucormycosis |
Maxilla, completely edentulous*** |
Orthopanto- mography, Computed tomography |
Maxillectomy |
Definitive maxillary obturator |
5 years |
8. |
Shah R et al./ 2014 [10], India, (Case 2) |
42/ Female |
Unspecified |
Mucormycosis |
Maxilla*** |
Not specified |
Bilateral oronasal openings |
Definitive maxillary obturator |
>1 year |
9. |
Kalaskar et al./ 2016 [11], India |
18 months/ male |
Unspecified |
Rhinocerebral mucormycosis |
Aramany class IV |
Occlusal radiograph |
Amphotericin B |
Palatal obturator |
3 months |
10. |
Inbarajan et al./ 2018 [12], India |
60/ Female |
Unspecified |
Uncontrolled Type 2 Diabetes Mellitus, Mucormycosis |
Maxillary defect with completely edentulous arch*** |
Not mentioned |
Surgical debridement, oronasal fistula |
Definitive maxillary obturator |
3 months |
11. |
Manjunath et al./ 2018 [13], India |
Elderly female |
Unspecified |
Uncontrolled Type 2 Diabetes Mellitus, Mucormycosis |
Maxilla*** |
Computed tomography |
Surgical debridement Amphotericin B |
Interim maxillary obturator |
3 weeks |
12. |
Salinas TJ et al./ 2019 [14], Rochester, Minnesota |
32/ Female |
Unspecified |
Lymphoblastic Lymphoma, Chemotherapy, Invasive mucormycosis |
Aramany Class VI |
Unspecified |
Serial debridement of the maxilla, anterior maxillectomy, right intranasal, and alar resection followed by microvascular free flap |
Interim acrylic obturator followed by metal-ceramic fixed prosthesis supported by 8 osseointegrated dental implants. |
Unspecified |
13. |
Mani UM et al./ 2019 [15], India |
64/Male |
Zygomyces |
Uncontrolled diabetes |
Aramany class IV |
Unspecified |
Total maxillectomy on left side and right subtotal maxillectomy |
Split thickness graft was done in lateral wall of the defect, maxillary definitive 2-piece hollow obturator |
|
14. |
Punjabi et al./ 2019 [16], India |
50/ Male |
Unspecified |
Uncontrolled diabetes, Mucormycosis |
Aramany class VI |
Not specified |
Resection of hard palate and maxilla |
Definitive obturator with silicone relined titanium bulb |
Not specified |
Case reports after 2019 |
|||||||||
15. |
Pandilwar PK et al./ 2020 [17], India |
60/ Male |
Unspecified |
Uncontrolled diabetes Rhinomaxillary Mucormycosis |
Completely edentulous maxilla*** |
Orthopantomogram and Cone-beam computed tomography |
Total maxillectomy |
Interim palatal obturator |
Not specified |
16. |
Pandilwar PK et al./ 2020 [17], India |
67/ Male |
Unspecified |
Uncontrolled diabetes, Mucormycosis |
Maxilla*** |
Cone-beam computed tomography |
Surgical debridement of maxilla Amphotericin B |
Palatal obturator |
2 months |
17. |
Mohamed et al./ 2020 [18], India |
48/ Male |
Unspecified |
Invasive mucormycosis |
Left maxilla*** |
Unspecified |
Hemi maxillectomy |
Delayed surgical obturator |
Not specified |
18. |
Mohamed et al./ 2020 [18], India |
55/ Male |
Unspecified |
Mucormycosis |
Maxilla*** |
Unspecified |
Bilateral complete maxillectomy |
Delayed surgical obturator |
Not specified |
19. |
Eswaran et al./ 2021 [19], India** |
31/ Male |
Mucorales |
Covid 19, Mucormycosis |
Aramany class IV |
MRI, Computed tomography |
Liposomal Amphotericin B, Polymixin B injection, Bilateral oral Posaconazole maxillectomy and right frontal craniectomy with Debridement and repair with Titanium mesh. |
Interim obturator |
One month |
20. |
Ravi MB et al./ 2022 [20], India (case 1) * |
34/ Female |
Rhizopus |
Uncontrolled Diabetes / COVID 19/ Mucormycosis |
Aramany class I |
Unspecified |
Surgical debridement and resection of right maxilla, Piperacillin, Tazobactam Posaconazole Insulin |
Hollow sectional magnet retained prosthesis |
Unspecified |
21. |
Ravi MB et al./ 2022 [20], India (case 2) * |
60/ Male |
Broad aseptate hyphae of Mucorales. |
Diabetes / COVID 19/ Right Rhinosinomaxillary Mucormycosis with Left Mucormycosis |
Aramany Class IV |
Gadolinium enhanced MRI, a plain Computed tomography of para nasal sinuses |
Right Total Maxillectomy and left Hemi maxillectomy Posaconazole Amphotericin |
Hollow bulb obturator |
24, 48, and 72 hours of denture insertion. |
22. |
Kondaka S et al./2022 [21], India* |
40/ Male |
Not mentioned |
Diabetes/ Post Covid Mucorm- ycosis |
Bilateral maxille- ctomy*** |
Post surgical debridement CBCT |
Left total Maxillectomy, right subtotal maxillectomy and left orbital decompression along with the resection of the left zygomatic arch and rim. |
Obturator supports by patient specific implants |
Till 90 days. |
23. |
Rathee M et al./2022 [22], India (Case 1)* |
50/Male |
Not mentioned |
Diabetes/ Post Covid Rhinocerebral Mucormycosis |
Aramany Class II |
CT scan |
Surgical debridement |
Immediate Surgical obturator |
Not specified |
24. |
Rathee M et al./2022 [22], India (Case 2)* |
24/Male |
Not mentioned |
Early onset Diabetes, Post COVID Mucormycosis |
Aramany Class III |
Not specified |
Surgical debridement |
Immediate Surgical obturator |
Not specified |
25. |
Rathee M et al./2022 [22], India (Case 3)* |
40/Male |
Not mentioned |
Diabetes, Post COVID Mucormycosis |
Aramany Class III |
Not specified |
Surgical debridement |
Immediate Surgical obturator |
Not specified |
26. |
Rathee M et al./2022 [22], India (Case 4) |
46/Female |
Not mentioned |
Diabetes, PCM |
Aramany Class III |
Functional endoscopic sinus surgery |
Surgical debridement |
Interim obturator |
3 months or more |
27. |
Rathee M et al./2022 [22], India (Case 5) |
56/Male |
Not mentioned |
Post Covid Rhinocerebral mucormycosis |
Completely edentulous*** |
Not mentioned |
Partial maxillectomy |
Interim obturator/ Magnet retained definitive 2 part prosthesis |
Not mentioned |
28. |
Rathee M et al./2022 [22], India (Case 6) |
48/Male |
Not mentioned |
Post Covid Rhinocerebral mucormycosis |
Completely edentulous*** |
Not mentioned |
Total maxillectomy |
Interim obturator/ Definitive magnet retained obturator |
Not mentioned |
29. |
Rathee M et al./2022 [22], India (Case 7) |
65/Male |
Not mentioned |
Diabetes, Post Covid Rhinocerebral mucormycosis |
Class IV |
Not mentioned |
Partial maxillectomy |
Interim obturator |
Not mentioned |
30. |
Rathee M et al./2022 [22], India (Case 8) |
46/ Male |
Not mentioned |
Rhinocerebral mucormycosis |
Not specified |
Not mentioned |
Partial maxillectomy |
Interim obturator |
Not mentioned |
31. |
Rathee M et al./2022 [22], India (Case 9) |
38/Female |
Not mentioned |
Diabetic, PCM |
Aramany Class I? / Closed flap*** |
Not mentioned |
Hemi maxillectomy |
Definitive cast partial denture |
|
32. |
Artopoulou I et al./ 2022 [23], Greece |
53/Male |
Rhizopus |
Diabetes, PCM |
Closed with palatal flap*** |
CT scan |
Bilateral subtotal maxillectomy with aggressive debride ment |
Definitive obturator with bilateral acrylic projections |
6 months |
|
Author/ Year Country |
Age/ Gender |
Genus/ Species |
Risk Factors |
Location |
Imaging tests |
Treatment |
Rehabilitation |
Follow-up |
|
1. |
Dhiman R et al./ 2007, India, |
17/ Male |
Unspecified |
Uncontrolled diabetes and Mucormycosis |
Aramany class IV |
Not mentioned |
Subtotal right maxillectomy and enucleation of right eye |
Magnet-retained, silicone eye prosthesis and a polymethyl-methacrylate hollow bulb obturator. |
Unspecified |
Rehabilitation of a rhinocerebral mucormycosis patient. The Journal of Indian Prosthodontic Society. 2007;7(2):88-91. |
2. |
Rathee et al./ 2013, India |
68/ Male |
Unspecified |
Uncontrolled diabetes, Rhinocerebral Mucormycosis |
Anterior maxilla*** |
None |
Surgical debridement of maxilla |
Interim palatal obturator |
Not mentioned |
Management of Palatal Perforation in an Immunocompromised Diabetic Patient with Mucormycosis Using Surgical and Interim Obturator. Int J Clin Cases Investig 2013;5:63:67. |
3. |
Naveen et al./ 2015, India |
48/ Male |
Unspecified |
Uncontrolled diabetes, Rhinocerebral Mucormycosis |
Maxilla, Aramany Class IV |
Computed tomography, panoromic radiograph |
Partial maxillectomy, Amphotericin B |
Hollow bulb definitive obturator |
Not specified |
Mucormycosis of the Palate and its Post-Surgical Management: A Case Report. J Int Oral Heal 2015;7:134. |
4. |
Ilusika et al./ 2018, India |
47/ Male |
Mucorales |
Diabetes, Mucormycosis |
Aramany Class VI |
Computed tomography |
Fluconazole tablets 200 mg for 12 days, Surgical debridement |
Definitive obturator |
5 months |
Enhancing granulation in a postmucormycotic maxillectomy defect with honey: A review of literature and illustrative case. Niger J Basic Clin Sci 2018;15:156-60. |
5. |
Abrol et al./ 2019, India |
44/ Male |
Unspecified |
Mucormycosis with osteomyelitis |
Aramany Class IV |
Not mentioned |
Surgical debridement |
Definitive maxillary obturator |
2 months |
Prosthodontic Management of Sub-Total Maxillectomy: A Case Report. Chronicles Dent Res 2019;8:61-5. |
6. |
Bandari et al./2021, India* |
65/ Male |
Unspecified |
Post covid mucormycosis |
Aramany class IV |
Not mentioned |
Left maxillectomy |
Hollow bulb obturator |
Unspecified |
Prosthetic Rehabilitation of A Post-Covid Mucormycosis Maxillectomy Defect Using A Fused Two-Piece Hollow Obturator: A Fabrication Technique. Eur J Mol & Clin Med 2021;7:8564-9. |
7. |
Rafique et al./ 2020, Pakistan |
65/ Female |
Unspecified |
Type 2 Diabetes, Mucormycosis |
Maxilla and extraoral defect** |
Not mentioned |
Partial maxillectomy, completely edentulous |
Magnet retained defintive obturator |
One week |
Restoration of a post-surgical defect by magnetic maxillofacial prosthesis: A case report. J Univ Med |
8. |
Prakash M et al./ 2020, India |
26/ Male |
Unspecified |
Kidney transplantation, Mucormycosis |
Maxilla** |
Unspecified |
Partial maxillectomy |
Cast metal maxillary definitive obturator |
Unspecified |
Prosthodontic Rehabilitation of Maxillary Defect in a Patient with Mucormycosis. J Evol Med Dent Sci 2020;9:3163-7. |
9. |
Mishra et al./ 2021, India |
64/ Male |
Unspecified |
Rhinocerebral mucormycosis |
Right maxilla, Aramany class II |
Unspecified |
Right maxillectomy |
Cast metal maxillary defintive obturator |
Unspecified |
Prosthetic Rehabilitation of Maxillectomy Defects, with Single-Piece Open-Hollow Bulb Definitive Obturator. J Evol Med Dent Sci 2021;10:1169-74. |
10. |
Garde J et al./2021, India* |
55/ Female |
Broad, aseptate, ribbon shaped hyaline fungal hyphae seen. |
Post covid mucormycosis |
Aramany class IV |
CT-PNS: MRI-PNS |
Bilateral Subtotal Maxillectomy |
Definitive maxillary obturator |
1 month and at 8 months |
Restoring a Smile Post Covid-19 Associated Mucormycosis: A Case Report. J Dental Sci 2021, 6(4): 000314. |
11. |
Shilpa et al./ 2021, India |
52/ Male |
Unspecified |
Diabetes mellitus |
Aramany Class VI |
Unspecified |
Hemi maxillectomy |
Cast metal hollow obturator |
3 months |
A case report on prosthetic rehabilitation of a patient with hemimaxillectomy: A modified technique. J Int Oral Heal. 2021;13:306-9. |
12. |
Chinta A et al./ 2022, India |
24/Male |
Unspecified |
Diabetes mellitus Rhinosinomaxillary mucormycosis and right Mucormycosis |
Aramany Class IV |
Anterior diagnostic rhinoscopy |
Left total maxillectomy and right hemimaxillectomy |
Definitive hollow acrylic obturator |
3 months |
Prosthodontic rehabilitation of a mucormycosis patient: a case report |
13. |
Shalimon A et al./2023*, India |
47/Male |
Unspecified |
Rhino orbital mucormycosis (Post COVID?)*8 |
Not clear** |
Presented after resection |
Right hemi maxillectomy |
Cast metal obturator |
Not specified |
Prosthetic rehabilitation of post-COVID mucormycosis. J Interdiscip Dentistry 2023;13:43-7 |
14. |
Nagpal A et al./ 2022, India |
24/Male |
Unspecified |
Mucormycosis |
Brown’s class IIb** |
Presented after resection |
Unilateral maxillary defect not crossing midline |
Cast metal obturator |
Not specified |
Prosthetic Rehabilitation of Mucormycosis Patient By Cast Partial Denture: A Case Report. Bull. Env. Pharmacol. Life Sci., Spl Issue[2] 2022 : 235-237 |


Data Acquisition and Observations
Literature search was performed on PubMed and Google scholar/ Google for patients who had a history of Mucormycosis and underwent prosthodontic rehabilitation from 2007 to 18th May 2023. 14 more cases could be found on PubMed (Table 1) and 5 on google scholar (Supplementary table with references) with same etiology and treatment during the same time frame (2007-2019).[4], [5], [6], [7], [8], [9], [10], [11], [12], [13], [14], [15], [16] In addition, Abu El-Naaj et al (2013) have reported 5 patients with history of mucormycosis who succumbed to the disease before they could be rehabilitated with maxillary obturator. [5]
I. E. Ali, et al reported prosthodontic rehabilitation of post mucormycosis defects from 30 case reports published between 2010 to 2021. [24] 18 more patients on PubMed [17], [18], [19], [20], [21], [22], [23] and 9 on google scholar [[Table 2]] were reported with history of mucormycosis followed by fabrication of palatal obturator from 2020 to May 2023. Mean age and gender wise distribution of patients who were rehabilitated after surgical management of mucormycosis has been depicted in [Figure 1]. A clear predilection of male patients is evident over females with age range between 18 months to 75 years.
As aptly emphasized by other authors that most of the cases were reported from India, a discussion about post covid mucormycosis is worth mentioning. Our data shows that approximately 80% of patients were reported from India. Previous literature has also reported global prevalence of mucormycosis to be 70 times more in India, though other countries also faced the heat of the situation. [2] Covid-19 virus infected patients with diabetes were predisposed at a higher rate to the invasion of fungus owing to a compromised host defence mechanism. One of the scientific rationales behind this could be existence of proviral and profungal cellular host factors in olfactory epithelium of diabetic patients, which makes them vulnerable to upper respiratory infections, owing to their higher glucose levels and lowered immunity. [25] In general, the spores of fungus find a favourable niche in pterygomandibular fossae from where they invade different structures.[26] Although the data is extensive on different manifestations of post covid mucormycosis, Moorthy et al have specifically documented history of 11 patients who underwent maxillectomy, out of which 4 patients did not survive this deadly fungal infection.[27] Recent case reports have documented 10 patients with history of post covid mucormycosis (PCM) who were efficiently rehabilitated with obturators ([Table 1], [Table 2]). [19], [20], [21], [22], [23], [28], [29]
Diabetes mellitus was the most significant associated risk factor in 27 patients followed by Acute Myeloid Leukemia based on data reported here and earlier by Santos et al. Rhizopus oryzae has been reported to be the most common causative organism as high glucose levels, insulin resistance and ketoacidosis encourage its growth.[30] Amphotericin B remained the first-choice drug followed by Posaconazole. Follow up period was inconsistent in all the case reports with only one patient followed till 5 years by Shah et al. [10] Probable reasons for short term follow up could be because of aggressive nature of disease, poor general health of patients, uncertain family support and difficult accessibility to healthcare services, especially in developing countries.
Few authors performed extensive debridement in patient diagnosed with mucormycosis but did not mention any prosthetic rehabilitation. [31], [32] So, here i would like to emphasize that diagnosis and management of patients with mucormycosis consist of a multidisciplinary team, where a huge onus lies on the maxillofacial prosthodontist. They play a crucial role by helping in social reintegration of patients by their functional and aesthetic rehabilitation. Various authors have provided either a hollow obturator, sectional prosthesis, or innovative designs to retain prothesis in orbito maxillary defects but there are many case reports in which the performance of obturator was not mentioned. Another critical aspect is reporting of patient satisfaction, which was measured subjectively with Oral health Impact Profile – 14 questionnaires in only two case reports and were found to be improved on Likert scale after prosthodontic rehabilitation. [9], [12] Artopoulou I et al used Obturator Functioning Scale and Distress Scale to evaluate the patient satisfaction and psychological status respectively. [23]
Early diagnosis of condition, treatment of underlying pathology, thorough debridement, antifungal drugs, local care of post debridement wound, psychological counselling and prosthodontic rehabilitation are integral components of a comprehensive treatment plan for such patients. [25] In a breakthrough research, Sharma et al have proposed the future of intranasal sprays with anti-inflammatory, anti-diabetic and antiviral action which would help in prophylactic control of mucormycosis in covid infected and/ or diabetic patients. Exact formulation of drugs is still unpublished, but it can be a promising therapy for preventing the spread of infection. [25]
I would like to highlight the huge discrepancy which was noticed among the references quoted in Table 1 and reference list given at the end of article by Santos et al. [3] So, the readers should follow correct references to prevent further error while quoting the literature. Last but not the least, this article has reported those case reports which have been already documented in literature, though the number of patients who might have suffered with PCM must be much larger. Data from large tertiary care hospitals from India need to be added for complete reporting of the evidence. Follow up of the patients should be provided by the authors as an integral part of comprehensive treatment plan. In view of incomplete reporting and lack of adequate follow up in most of the case presentations to report patient survival, improvement in quality of life or performance analysis of the prosthesis delivered in terms of functional, esthetic, or psychological benefit, I am unable to document any robust evidence on effect of prosthodontic rehabilitation of such patients.
Another interesting finding is that although maximum number of defects were classified as Class IV (n=12) according to Aramany’s classification, [33] many authors did not classify the post resection defects. One of the reasons could be inability to fit the post mucor especially post covid mucor defects into any class of defects due to extensive and emergency management with overburdening of the system. Authors should ensure to consider this important component of presenting any case report and formulation of a more comprehensive single classification system to classify maxillofacial defects may be considered in future.
Conflict of Interest
There are no conflicts of interest in this article.
Source of Funding
None.
References
- Leitner C, Hoffmann J, Zerfowski M, Reinert S. Mucormycosis: Necrotizing Soft Tissue Lesion of the Face. J Oral Maxillofac Surg. 2003;61(11):1354-8. [Google Scholar]
- Prakash H, Chakrabarti A. Global Epidemiology of Mucormycosis. J Fungi (Basel). 2019;5(1). [Google Scholar] [Crossref]
- Santos RD, Elchin C, Guiguer-Pinto V, Vasconcelos D, Ferreira M, Dias R. Diagnosis, treatment and maxillofacial rehabilitation in rhinocerebral mucormycosis patient: A case report and review of the literature. J Mycol Med. 2022;32(1). [Google Scholar] [Crossref]
- IE, Leiser Y, Wolff A, Peled M, . The surgical management of rhinocerebral mucormycosis. J Craniomaxillofac Surg. 2013;41(4):291-5. [Google Scholar] [Crossref]
- Hatami M, Badrian H, Samanipoor S, Goiato M. Magnet-retained facial prosthesis combined with maxillary obturator. Case Rep Dent. 2013. [Google Scholar] [Crossref]
- Gowda M, Mohan M, Verma K, Roy I. Implant rehabilitation of partial maxil lectomy edentulous patien. Contemp Clin Dent. 2013;4(3):393-6. [Google Scholar] [Crossref]
- Vidyasankari N, Kumar CD, Sharma N, Yogesh S, Ramesh. Rehabilitation of a Total Maxillectomy Patient by Three Different Methods. J Clin Diagnostic Res JCDR. 2014;8(10):ZD12-4. [Google Scholar] [Crossref]
- Faheemuddin M, Yazdanie N, Nawaz MS. Impact of prosthodontic treatment on the oral health related quality of life in a maxillectomy patient with multiple impairments. J Ayub Med Coll Abbottabad. 2014;26(2):246-51. [Google Scholar]
- Shah R, Katyayan M, Katyayan P, Chauhan V. Prosthetic rehabilitation of acquired maxillary defects secondary to mucormycosis: clinical cases. J Contemp Dent Pract. 2014;15(2):242-9. [Google Scholar] [Crossref]
- Kalaskar R, Kalaskar A, Ganvir S. Oral mucormycosis in an 18-month-old child: a rare case report with a literature review. J Korean Assoc Oral Maxillofac Surg. 2016;42(2):105-10. [Google Scholar] [Crossref]
- Inbarajan A, Natarajan S, Thangarajan S, Seenivasan M, Banu F, VK. Impact of Prosthodontic Treatment on the Oral Health-related Quality of Life in Mucormycosis Patient: A Case Report. Cureus. 2018;10(10). [Google Scholar] [Crossref]
- Manjunath N, Pinto P. Management of recurrent rhinomaxillary mucormycosis and nasal myiasis in an uncontrolled diabetic patient: A systematic approach. Int J App Basic Med Res. 2018;8(2):122-5. [Google Scholar] [Crossref]
- Salinas TJ, Sinha N, Revuru V, Arce K. Prosthetic rehabilitation of a maxillary defect with a bone anchored prosthesis: A clinical report. J Prosthet Dent. 2019;121(1):173-78. [Google Scholar] [Crossref]
- Mani U, Mohamed K, Kumar A, AI, A. A modified technique to fabricate a complete hollow obturator for bilateral maxillectomy in a patient with mucormycosis-A technical case report. Spec Care Dentist. 2019;39(6):610-16. [Google Scholar]
- Punjabi A, Mistry G, Shetty O, Rathod A. Maxillary hollow-bulb obturator: A paradigm shift. J Indian Prosthodont Soc. 2019;19(1):74-8. [Google Scholar] [Crossref]
- Pandilwar P, Khan K, Shah K, Sanap M, Au K, Nerurkar S. Mucormycosis: A rare entity with rising clinical presentation in immunocompromised hosts. Int J Surg Case Rep. 2020;77:57-61. [Google Scholar] [Crossref]
- Mohamed K, Mohanty S. Delayed Surgical Obturator-Case Series. Indian J Surg Oncol. 2020;11(1):154-8. [Google Scholar] [Crossref]
- Eswaran S, Balan S, Saravanam P. Acute Fulminant Mucormycosis Triggered by Covid 19 Infection in a Young Patient. Indian J Otolaryngol Head Neck Surg. 2022;74(Suppl 2):3442-6. [Google Scholar] [Crossref]
- Ravi MB, Srinivas S, Silina E, Sengupta S, Tekwani T, Achar RR. Prosthetic Rehabilitation of Rhino Orbital Mucormycosis Associated with COVID-19: A Case Series. Clin Cosmet Investig Dent. 2022;14:1-10. [Google Scholar] [Crossref]
- Kondaka S, Singh V, Vadlamudi C, Bathala L. Prosthetic rehabilitation of untailored defects using patient-specific implants. Dent Res J (Isfahan). 2022;19. [Google Scholar]
- Rathee M, Divakar S, Jain P, Alam M, Singh S. Post maxillectomy rehabilitation and amelioration of quality of life of post-COVID rhinocerebral mucormycosis patients using obturator- A case series. J Family Med Prim Care. 2022;11(11):7476-82. [Google Scholar] [Crossref]
- Artopoulou II, Kalfarentzos E, Polyzois G, Perisanidis C. Prosthodontic restoration of a COVID-19 associated mucormycosis defect: A clinical report. Spec Care Dentist. 2022. [Google Scholar] [Crossref]
- Pruthi G, Jain V, Sikka S. A Novel Method for Retention of an Orbital Prosthesis in a Case with Continuous Maxillary and Orbital Defect. J Indian Prosthodont Soc. 2010;10(2):132-6. [Google Scholar] [Crossref]
- Ali IE, Chugh A, Cheewin T, Hattori M, Sumita YI. The rising challenge of mucormycosis for maxillofacial prosthodontists in the Covid-19 pandemic: A literature review. J Prosthodont Res. 2022;66(3):395-401. [Google Scholar]
- Sharma M, Vanam H, Panda N, Patro S, Arora R, Bhadada S. Deciphering the Neurosensory Olfactory Pathway and Associated Neo-Immunometabolic Vulnerabilities Implicated in COVID-Associated Mucormycosis (CAM) and COVID-19 in a Diabetes Backdrop-A Novel Perspective. Diabetology. 2022;3(1):193-235. [Google Scholar]
- Hosseini S, Borghei P. Rhinocerebral mucormycosis: pathways of spread. Eur Arch Otorhinolaryngol. 2005;262(11):932-940. [Google Scholar] [Crossref]
- Moorthy A, Gaikwad R, Krishna S, Hegde R, Tripathi K, Kale P. SARS-CoV-2, Uncontrolled Diabetes and Corticosteroids-An Unholy Trinity in Invasive Fungal Infections of the Maxillofacial Region? A Retrospective, Multi-centric Analysis. J Maxillofac Oral Surg. 2021;20(3):418-25. [Google Scholar] [Crossref]
- Mounika K, Kumar M, Babu M, Kishore K, Reddy M, Bandari G. Prosthetic Rehabilitation of A Post-Covid Mucormycosis Maxillectomy Defect Using A Fused Two-Piece Hollow Obturator: A Fabrication Technique. Eur J Mol Clin Med. 2021;7:8564-9. [Google Scholar]
- Garde J, Khan A, Dhande S, Garde D, Muglikar S. Restoring a Smile Post Covid-19 Associated Mucormycosis: A Case Report . J Dental Sci. 2021;6(4). [Google Scholar] [Crossref]
- Morales-Franco B, Nava-Villalba M, Medina-Guerrero E, Sánchez-Nuño Y, Davila-Villa P, Anaya-Ambriz E. Host-Pathogen Molecular Factors Contribute to the Pathogenesis of Rhizopus spp. in Diabetes Mellitus. Curr Trop Med Rep. 2021;8(1):6-17. [Google Scholar] [Crossref]
- Alekseyev K, Didenko L, Chaudhry B. Rhinocerebral Mucormycosis and COVID-19 Pneumonia. J Med Cases. 2021;12(3):85-9. [Google Scholar] [Crossref]
- Verma A, Singh V, Jindal N, Yadav S. Necrosis of maxilla, nasal, and frontal bone secondary to extensive rhino-cerebral mucormycosis. Natl J Maxillofac Surg. 2013;4(2):249-51. [Google Scholar] [Crossref]
- Aramany M. Basic principles of obturator design for partially edentulous patients. Part I: Classification. J Prosthet Dent. 1978;40(5):554-7. [Google Scholar] [Crossref]
How to Cite This Article
Vancouver
Pruthi G. Prosthodontic rehabilitation of patients with Rhinocerebral mucormycosis: An update of evidence [Internet]. IP Ann Prosthodont Restor Dent. 2023 [cited 2025 Sep 22];9(2):117-128. Available from: https://doi.org/10.18231/j.aprd.2023.024
APA
Pruthi, G. (2023). Prosthodontic rehabilitation of patients with Rhinocerebral mucormycosis: An update of evidence. IP Ann Prosthodont Restor Dent, 9(2), 117-128. https://doi.org/10.18231/j.aprd.2023.024
MLA
Pruthi, Gunjan. "Prosthodontic rehabilitation of patients with Rhinocerebral mucormycosis: An update of evidence." IP Ann Prosthodont Restor Dent, vol. 9, no. 2, 2023, pp. 117-128. https://doi.org/10.18231/j.aprd.2023.024
Chicago
Pruthi, G.. "Prosthodontic rehabilitation of patients with Rhinocerebral mucormycosis: An update of evidence." IP Ann Prosthodont Restor Dent 9, no. 2 (2023): 117-128. https://doi.org/10.18231/j.aprd.2023.024